Profiling of Oncology Patients as Part of Clinical Care and Research (PROSPER)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03158636|
Recruitment Status : Recruiting
First Posted : May 18, 2017
Last Update Posted : November 4, 2020
The era of precision medicine is an exciting time for clinicians, scientists and patients alike. The increasing appreciation and identification of specific mutations that drive cancers, leaves us on the threshold of a new era in which biomarkers will be used to direct targeted agents to only those patients most likely to respond. The potential medical and scientific benefits of such a personalised approach to cancer therapy are immense. However, a number of barriers challenge successful implementation of this approach of which spatial and temporal heterogeneity are a major concern.
Gynaecological cancers are a major cause of mortality and morbidity internationally. In Auckland 150 new patients with ovarian, endometrial or cervical cancer are seen by a medical oncologist each year. In general, when these diseases recur, there are few effective therapeutic options and prognosis is poor. Better therapeutic targets and treatments are an unmet need across these tumour types with treatment paradigms still based upon platinum based therapy.
PROSPER (Profiling of Oncology Patients as part of Clinical care and Research) will investigate the evolution of gynaecological cancers over time and in response to treatment to develop better biomarkers to guide treatment decisions and ultimately improve patient outcomes. Biopsies at relapse will be collected and profiled with a 580 cancer gene panel. Circulating tumour DNA will be collected and analysed alongside biopsies as a potential non-invasive alternative. Linking genomic and clinical data will allow us to learn more to begin to change our paradigm of care.
|Condition or disease|
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||120 participants|
|Target Follow-Up Duration:||3 Years|
|Official Title:||Profiling of Oncology Patients as Part of Clinical Care and Research|
|Study Start Date :||September 2016|
|Estimated Primary Completion Date :||August 2021|
|Estimated Study Completion Date :||August 2021|
- Utilisation rates of molecular profiling information. [ Time Frame: 3 years ]
- Number of patients where the molecular profiling information guided standard treatment or clinical trial enrollment. [ Time Frame: 3 years ]
- Clinical trial accrual rates among patients with available molecular profiling data. [ Time Frame: 3 years ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03158636
|Contact: Michelle Wilson, MBChb, FRACPfirstname.lastname@example.org|
|Contact: Lindsey Wylde, MSc(Res)||+email@example.com|
|University of Auckland / Auckland City Hospital||Recruiting|
|Auckland, New Zealand, 1142|
|Contact: Michelle Wilson, MBChb, FRACP +64211561492 MiWilson@adhb.govt.nz|
|Contact: Louise M Clement, MA +6499234626 Louise.Clement@auckland.ac.nz|
|Principal Investigator: Michelle Wilson, MBChb, FRACP|
|Principal Investigator: Michael Findlay, MBChb, FRACP, MD|
|Principal Investigator:||Michelle Wilson, MBChb, FRACP||University of Auckland, New Zealand|